Literature DB >> 6298516

Different receptors mediate morphine-induced prolactin and growth hormone release.

K Spiegel, I A Kourides, G W Pasternak.   

Abstract

Morphine has a variety of actions on the release of pituitary hormones in addition to its analgesic actions. In the rat, morphine releases prolactin and growth hormone at doses comparable to those active in the tailflick analgesic assay. Naloxazone selectively inhibits the high affinity (mu 1) binding site and dramatically decreases morphine's analgesic potency for over 24 hours. In an effort to determine the opiate receptor mechanisms of morphine-induced prolactin and growth hormone release, groups of rats were treated with either naloxone or naloxazone and 24 hours later the prolactin and growth hormone response to morphine sulfate determined. Peak prolactin levels in the group treated the previous day with naloxone were very similar to levels in untreated controls. However, the peak prolactin levels in the group that received naloxazone the day before were depressed 80% (p less than 0.005). By contrast, growth hormone levels in the naloxazone-treated animals were actually higher than in the naloxone-treated group. Thus prolactin release, like analgesia, appears to be mediated through high affinity, or mu 1, sites, while growth hormone release is not.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298516     DOI: 10.1016/0024-3205(82)90112-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

2.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

3.  Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system.

Authors:  M A King; S Bradshaw; A H Chang; J E Pintar; G W Pasternak
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Methadone-induced hypoglycemia.

Authors:  Andrew J Faskowitz; Vladimir N Kramskiy; Gavril W Pasternak
Journal:  Cell Mol Neurobiol       Date:  2013-03-07       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.